Organon & Co. (NYSE: OGN), the Jersey City, New Jersey-based healthcare company focused on women’s health and established medicines, announced on October 16, 2026, positive interim Phase 3 findings supporting the contraceptive effectiveness of MIUDELLA, a hormone-free copper intrauterine system, through six years of use. The ongoing study reported a cumulative six-year Pearl Index of 0.93 pregnancies per 100 woman-years and an estimated Kaplan-Meier cumulative pregnancy rate of 3.9%. Sebela Women’s Health, which developed the product, will present the results at the Society of Family Planning’s 2026 Annual Meeting in San Francisco on October 17.
The analysis comes as the United States Food and Drug Administration reviews a supplemental New Drug Application seeking to extend MIUDELLA’s approved duration from three years to six years. The agency accepted the application in September 2026 and is expected to issue a decision during the second quarter of 2027. MIUDELLA received its original FDA approval in February 2025 for pregnancy prevention in females of reproductive potential for up to three years, and the newly reported longer-term results do not automatically change that authorization.
The six-year assessment included 465 participants from an original pregnancy-evaluable population of 1,397 and 592 from an original safety population of 1,601. Treatment-emergent adverse events included heavy menstrual bleeding, painful menstruation and pelvic discomfort, consistent with concerns already identified during the earlier development programme. Organon reported no new safety signals during the additional three years of follow-up, although the smaller population remaining under observation is important when interpreting the results.
Organon completed its agreement to obtain exclusive global commercialization rights to MIUDELLA from Sebela in June 2026. The product has a flexible nitinol-based frame and uses substantially less copper than the established Paragard device, providing a differentiated design within the hormone-free contraception market. The next commercial milestone will be determining whether the FDA accepts the extended efficacy and safety evidence, followed by broader product availability and physician adoption.
What does the 0.93 six-year Pearl Index mean for MIUDELLA’s effectiveness?
The Pearl Index is a conventional measure used in contraceptive research to describe the number of pregnancies occurring per 100 woman-years of exposure. A value of 0.93 indicates fewer than one pregnancy per 100 woman-years during the observed study exposure, according to the cumulative analysis. It is a rate-based measure and should not be interpreted as the percentage of participants who became pregnant during the entire six-year period.
Organon separately reported a cumulative Kaplan-Meier pregnancy estimate of 3.9% at six years, with a 95% confidence interval ranging from 2.7% to 5.8%. This measure accounts for the timing of observed pregnancies and participants’ periods of follow-up. Its interpretation differs from the Pearl Index, even though both help describe contraceptive effectiveness.
The distinction is important because an annualized rate cannot be multiplied mechanically by six to produce the observed cumulative probability of pregnancy. Participants may leave the study, discontinue the device or contribute different amounts of exposure over time. Statistical methods are used to account for these variations within the available data.
The reported Pearl Index had a 95% confidence interval of 0.62 to 1.34. This indicates that the estimate has statistical uncertainty, rather than establishing that every population using MIUDELLA will experience exactly the same pregnancy rate. The results are nevertheless consistent with substantial contraceptive activity through extended use.
The findings support further regulatory review but do not establish that MIUDELLA is more effective than competing intrauterine systems. Such a conclusion would require an appropriately designed comparison accounting for differences in study populations, follow-up and pregnancy assessment methods.
Why does the six-year analysis include fewer participants than the original study?
The ongoing Phase 3 investigation is a prospective, single-arm, multicenter study conducted by Sebela Women’s Health across 42 United States clinical sites. It originally enrolled women aged 17 to 45 years, with the pregnancy-evaluable population focused on participants aged 17 to 35. The programme was designed to establish contraceptive efficacy and safety, initially through three years and with extended follow-up continuing beyond that period.
The original pregnancy-evaluable population included 1,397 participants, while the broader safety population contained 1,601. At the six-year interim assessment, outcomes were available for 465 participants in the pregnancy-evaluable population and 592 in the safety population. These figures represent individuals reaching the relevant extended evaluation rather than the complete original enrollment.
A smaller long-term follow-up group is not unusual in prolonged contraceptive studies. Participants may discontinue treatment because they wish to conceive, experience adverse effects, change contraceptive preferences or leave the research programme for other reasons. However, the reasons for discontinuation and their relationship with pregnancy risk can influence the interpretation of longer-term results.
The October announcement does not provide a complete participant disposition table explaining every discontinuation over six years. It therefore does not establish that the women remaining at the final assessment were identical in characteristics and risk to those who left earlier. Full regulatory evaluation will need to consider how missing data and differing exposure durations affect the estimates.
The distinction also prevents a common misunderstanding. The cumulative Pearl Index and Kaplan-Meier estimates are based on the study’s available exposure and event information, not simply calculated by dividing a reported number of pregnancies by the 465 women remaining at six years.
How do the new findings compare with MIUDELLA’s original three-year data?
MIUDELLA was originally approved by the FDA on February 24, 2025, following clinical development involving three United States trials with a combined safety population of 1,904 women. The pivotal Phase 3 investigation provided the main efficacy evidence. In the original pregnancy-evaluable group of 1,397 women, the first-year Pearl Index was 0.94, with a 95% confidence interval of 0.43 to 1.78.
The cumulative three-year Pearl Index was 1.05, with a 95% confidence interval ranging from 0.66 to 1.60. Those findings supported the initial three-year indication, establishing that the device could provide effective hormone-free contraception within the approved period. The reported overall placement success rate was approximately 99% during the original programme.
The new cumulative six-year Pearl Index of 0.93 is numerically lower than the earlier three-year estimate. However, the difference should not be interpreted as evidence that MIUDELLA becomes more effective with longer use. The estimates reflect different observation periods, statistical denominators and participant exposure.
The key development is that the extended analysis did not reveal a substantial deterioration in the reported cumulative contraceptive rate. This provides additional evidence supporting the application for longer use. Nevertheless, the FDA must evaluate the full study data, including pregnancies, discontinuations and safety findings, before determining whether the indication can be extended.
The six-year results therefore represent an extension of the existing evidence rather than a new clinical trial establishing a different treatment mechanism.
How is MIUDELLA different from Paragard and other copper IUDs?
MIUDELLA is a hormone-free copper intrauterine system with a flexible frame made from nitinol, an alloy of nickel and titanium. The material’s elastic properties are intended to allow the device to accommodate variation in uterine anatomy. The design also includes a fully preloaded inserter with a tapered insertion tube measuring approximately 3.7 millimeters in diameter.
The device uses approximately 175 square millimeters of copper surface area, substantially less than the approximately 380 square millimeters associated with Paragard, the established United States copper IUD. Copper contributes to contraceptive activity by influencing the reproductive environment and interfering with fertilization. However, the amount of copper alone does not determine clinical effectiveness.
MIUDELLA’s lower copper load and flexible frame are intended to provide a differentiated product design. These characteristics may influence clinical interest, particularly among patients seeking hormone-free contraception. Nevertheless, they do not establish that insertion is less painful or that the device causes fewer bleeding-related symptoms than Paragard.
Paragard currently has a substantially longer established FDA-approved duration of use than MIUDELLA’s existing three-year label. A successful extension to six years would narrow that difference but would not establish equivalent duration or effectiveness. Product selection depends on individual needs and the evidence supporting each device.
The six-year MIUDELLA study is single-arm rather than a randomized head-to-head comparison with Paragard. Consequently, differences in reported event rates across the separate product studies should not be used to claim superiority in contraceptive performance or tolerability.
What did the long-term safety data show about bleeding and discomfort?
Heavy menstrual bleeding, dysmenorrhea and pelvic discomfort were among the treatment-emergent adverse events observed through six years of MIUDELLA use. These effects are relevant because bleeding changes and pain can influence whether patients continue using a copper intrauterine device. Even when contraceptive effectiveness is strong, tolerability may determine the product’s practical acceptability.
In the first year, 139 participants, corresponding to 8.7% of the reported safety population, discontinued treatment because of bleeding- or pain-related adverse events. During the sixth year, 11 participants, or 1.9% of the relevant annual population, discontinued for those reasons. These figures suggest fewer bleeding- and pain-related discontinuations among participants remaining under observation later in the study.
However, the decline should not be interpreted as definitive evidence that every individual’s symptoms improved by the same amount. Patients experiencing substantial adverse effects may have discontinued during earlier years, leaving a later population more likely to tolerate the device. This type of selection can influence long-term discontinuation patterns.
The company reported no new safety signals during the additional three years. That observation is encouraging, but it does not eliminate known risks associated with intrauterine contraception. Users may still experience expulsion, infection, perforation, pregnancy-related complications and other events requiring appropriate medical assessment.
Complete longer-term safety evaluation will require consideration of how many participants remained exposed and the severity of the reported events. The absence of a new safety signal is not equivalent to the absence of all adverse reactions.
Why does MIUDELLA require a special FDA safety programme?
MIUDELLA’s prescribing information includes a boxed warning concerning complications resulting from improper insertion. The product is available only through a Risk Evaluation and Mitigation Strategy, or REMS, intended to ensure that healthcare professionals are trained before inserting the device. The programme creates specific certification requirements for providers and relevant healthcare settings.
Healthcare professionals must complete the required training and enrollment before ordering and inserting MIUDELLA. Pharmacies and treatment facilities involved in dispensing or insertion must also meet the relevant certification requirements. These obligations are designed to reduce risks associated with incorrect placement rather than impose restrictions because the device contains hormones.
Improper insertion can contribute to uterine perforation, infection, abnormal bleeding, expulsion and pregnancy-related complications. Risks may be influenced by patient anatomy, recent childbirth, breastfeeding status and other medical circumstances. Appropriate clinical evaluation and insertion technique are therefore important components of safe use.
The device is contraindicated in several circumstances, including suspected pregnancy, certain uterine abnormalities, active pelvic inflammatory disease, Wilson’s disease and hypersensitivity to relevant materials. Patients should also be informed that intrauterine contraception does not protect against HIV or other sexually transmitted infections.
The extended six-year efficacy findings do not change these existing safety requirements. Any longer-duration approval would need to remain consistent with the FDA’s assessment of the device’s benefit-risk profile and the necessary precautions for clinical use.
What does the FDA’s supplemental application review mean for the six-year indication?
The FDA accepted Sebela Women’s Health’s supplemental New Drug Application in September 2026. The application seeks to expand MIUDELLA’s authorized duration of use from three years to six years, supported by the continuing Phase 3 programme. Organon has stated that the agency’s target action period is the second quarter of calendar year 2027.
Application acceptance confirms that the submission has entered review, not that the longer indication has been approved. The FDA may assess contraceptive efficacy, pregnancies occurring during extended use, safety events, participant retention and the statistical methods used to analyze follow-up. It may also review labeling and any related manufacturing or risk-management requirements.
Until the agency reaches a favorable decision, the United States-approved indication remains pregnancy prevention for up to three years. The reported six-year findings should not be interpreted as permission to disregard the current approved duration. Clinical use must follow the applicable prescribing information and professional guidance.
The extension would be commercially meaningful because a longer replacement interval could influence the attractiveness of the product to patients and clinicians. It might also affect the frequency of procedures required over several years. However, those benefits depend on regulatory authorization and the eventual evidence supporting routine longer-term use.
No specific approval date within the second quarter has been announced. The outcome remains subject to the FDA’s review.
How does Organon’s global licensing agreement with Sebela affect the opportunity?
Organon announced its agreement to license MIUDELLA from Sebela Women’s Health in February 2026 and completed the transaction in June. The agreement gives Organon exclusive global commercialization rights, allowing it to incorporate the product into its women’s health portfolio. Sebela remains central to the ongoing clinical development programme, including the extended Phase 3 investigation.
Under the original transaction terms, Organon agreed to pay $27.5 million at closing. Sebela is also eligible for up to $505 million in potential sales-based milestone payments, along with tiered double-digit royalties on net sales. These future payments depend on contractual conditions and should not be treated as guaranteed consideration.
The transaction is strategically relevant because Organon already operates an established women’s health business that includes contraceptive products. Adding a hormone-free intrauterine system broadens its portfolio and may allow the company to reach patients who prefer to avoid hormonal contraception. Its existing commercial infrastructure could support physician education and eventual market access.
However, clinical adoption is not guaranteed simply because Organon controls commercialization. Healthcare professionals must complete the REMS requirements, and providers will need to assess how MIUDELLA compares with existing options. Reimbursement and product availability will also influence uptake.
The company previously indicated that commercial availability was anticipated during late 2026. The October 16 announcement does not provide a confirmed nationwide launch date, initial sales volume or updated financial forecast for MIUDELLA.
What could a six-year approval mean for the hormone-free contraception market?
Patients considering long-acting reversible contraception often weigh effectiveness, duration, hormone exposure, procedural requirements and side effects. A copper intrauterine system provides a hormone-free option that does not require daily administration. However, insertion, potential bleeding changes and other medical considerations remain important factors in treatment selection.
An authorized six-year duration would allow MIUDELLA to serve patients seeking a longer replacement interval than its current three-year indication permits. This could improve its practical appeal while preserving a different design from other copper IUDs. Yet a longer indication alone would not prove greater effectiveness or tolerability than competing devices.
The expanded label could also strengthen Organon’s ability to market MIUDELLA alongside its existing contraceptive portfolio. Physician familiarity, appropriate training and reimbursement decisions will influence how extensively the product is adopted. The financial effect cannot currently be calculated from the reported clinical results.
The ongoing Phase 3 programme is designed to continue beyond the six-year interim analysis, with further follow-up planned. Such evidence may provide additional information about long-term effectiveness and adverse events. However, any subsequent extension would require its own regulatory assessment before being reflected in the approved label.
Organon’s October 2026 announcement provides a substantial clinical milestone for MIUDELLA, with a cumulative Pearl Index of 0.93 and an estimated 3.9% pregnancy probability through six years. The absence of newly identified safety signals supports continued evaluation, although the number of participants remaining under observation and the noncomparative study design remain important limitations.
The decisive next milestone is the FDA’s decision expected in the second quarter of 2027. A favorable outcome would extend the authorized life of MIUDELLA and potentially improve its competitiveness within the United States hormone-free contraceptive market. Until that decision, the product remains approved for three years, and the reported six-year performance should be understood as interim clinical evidence supporting a pending regulatory application.
